Common cold products
Common cold: Let’s get rid of it

Marinomed’s first marketed product based on the Carragelose® platform is a cold virus blocking nasal spray for the prevention and treatment of common cold. The product is a sterile nasal spray that is marketed in the EU and globally in a growing number of countries via renowned partners.

The product is registered as medical device class IIa in Europe since 2007 and is sold as an over-the-counter (OTC) product allowing direct to consumer marketing.

Key claims in EU:

  • Can shorten the duration and severity of common cold symptoms
  • Can reduce the resurgence of virus-related symptoms of common cold

Claims may vary in non-EU countries dependent on the regulatory status. 

Clinical studies were conducted with the virus blocking nasal spray against common cold, in adults and in small children.

Marinomed has received patents worldwide to protect the Carragelose® platform and its products. Patent protection lasts until end of 2027; the core patent was granted in the EU in 2010.

This product contains two Carragelose® polymers with a total amount of 1,6mg/ml and is specifically designed for the treatment of cold & flu-like illness. The product is a sterile nasal spray that is marketed in the EU and globally in a growing number of countries via renowned partners.

The product is registered as medical device class IIa in Europe and is sold as an over-the-counter (OTC) product allowing direct to consumer marketing.

Key claims in EU:

  • Can shorten the duration and severity of flu-like symptoms
  • Can reduce the resurgence of virus-related symptoms of a flu-like illness

Carragelose® polymers have shown exceptional activity against human and non-human influenza viruses. For further reading see: Iota-Carrageenan Is a Potent Inhibitor of Influenza A Virus Infection, Leibbrandt, et al. 2010, PLoS ONE.

Marinomed has received patents worldwide to protect the Carragelose® platform and its products. Patent protection lasts until end of 2027; the core patent was granted in the EU in 2010.

Carragelose® Lozenges are approved for children and adults above the age of 6 years in the EU. Each lozenge contains 10mg Carragelose®. A typical standard pack contains 2 blisters with 10 lozenges per blister. The lozenges are delivered with a honey-lemon flavor.

The product is registered as medical device class IIa in Europe and is sold as an over-the-counter (OTC) product allowing direct to consumer marketing. The registration status may change in future and might be different in non EU countries.

Key claims in EU:

  • For accompanying use in the treatment of viral infections of the respiratory tract
  • For preventive and sustained moistening of mouth and throat in case of dry breathing air, cough, hoarseness,…

Marinomed has received patents worldwide to protect the Carragelose® platform and its products. Patent protection lasts until end of 2027; the core patent was granted in the EU in 2010.

This product contains Carragelose® with a total amount of 1,2mg/ml and is especially designed for the accompanying treatment of viral infections of the upper respiratory tract. The product is a good treatment option for children who are too small for the use of lozenges.

Key claims in EU:

  • For accompanying use in the treatment of viral infections of the respiratory tract
  • For the prevention and supportive treatment of all complaints resulting from dry and/or irritated oral and pharyngeal mucosa caused by e.g. smoking, long speaking or singing.

Marinomed has received patents to protect the Carragelose® platform and its products in all important markets including Europe, United States, Japan, Eurasia and many more. Patent protection lasts until end of 2028; the core patent was granted in the EU in 2010.

This formulation has been developed in Marinomed’s laboratories in order to optimize the efficacy of Carragelose® with the addition of a decongestant effect based on increased osmolality. Instead of sodium chloride (NaCl), which also has an osmotic effect, a new formulation is used to retain the activity of Carragelose® against viruses infecting the respiratory tract.

For this product a special IP-protection in addition to the Carragelose® core patents applies and is valid until 2036.

This product in development will combine the virus blocking effect of Carragelose® with the decongestant effect of the well-known pharmaceutical compound Carragelose®.